Gene therapy to cure leukemia at one-tenth global costs in the works

ImmunoACT, backed by Laurus Labs is testing their cancer product

Chip-based cancer test may replace painful bone biopsy

Representative image

ImmunoACT, an IIT-Bombay spin-off backed by Hyderabad-based Laurus Labs, is testing a new gene-therapy treatment for cancer, which they claim would not only cure the disease, but also costs one-tenth

Also Read

Growth trajectory, margins anc client additions to sustain for Laurus Labs

Irdai asks insurers to review claims denied for antibody cocktail therapy

Can easing regulatory norms for gene-edited crops compromise bio-safety?

Laurus Labs bounces 16% from day's low on heavy volumes

Laurus Labs up 8% in two days on purchase orders from global pharma company

Latest LIVE: 12th WTO meeting begins today, Goyal to lead Indian delegation

Mumbai police summons Nupur Sharma for her remarks against Prophet Mohammad

Assam will acquire land first, then send proposal to Centre for airport: CM

Assam govt keeping close watch on law and order situation: CM Himanta Biswa

Visa on time: Embassies work to meet spike in applications by Indians

First Published: Jun 12 2022 | 9:38 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to